-
Emergency department-initiated buprenorphine protocols: A national evaluation.
Guo CZ, D'Onofrio G, Fiellin DA, Edelman EJ, Hawk K, Herring A, McCormack R, Perrone J, Cowan E. Emergency department-initiated buprenorphine protocols: A national evaluation. Journal of the American College of Emergency Physicians Open 2021;2:e12606.
-
Clinician perceptions about a decision support system to identify and manage opioid use disorder.
Solberg LI, Hooker SA, Rossom RC, Bergdall A, Crabtree BF. Clinician perceptions about a decision support system to identify and manage opioid use disorder. Journal of the American Board of Family Medicine 2021;34:1096-1102.
-
Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: A qualitative analysis.
Hoffman KA, Baker R, Fanucchi LC, Lum PJ, Kunkel LE, Terashima JP, McCarty D, Jacobs P, Korthuis PT. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: A qualitative analysis. Addiction Science & Clinical Practice 2021;16:67.
-
Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.
Roache JD, Pavlicova M, Campbell ANC, Choo T, Peavy M, Kermack AS, Nunes EV, Rotrosen J. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. Alcoholism: Clinical and Experimental Research 2021;45(12):2569-2578.
-
Optimizing opioid use disorder treatment with naltrexone or buprenorphine.
Rudolph KE, Diaz I, Luo SX, Rotrosen J, Nunes EV. Optimizing opioid use disorder treatment with naltrexone or buprenorphine. Drug and Alcohol Dependence 2021;228:109031.
-
Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.
Montgomery L, Winhusen TJ, Scodes J, Pavlicova M, Twitty D, Campbell ANC, Wang AL, Nunes EV, Rotrosen J. Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2021;130:108489.
-
Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO Alcohol, Smoking, and Substance Involvement Screening Test.
Cochran G, Brown J, Yu Z, Frede S, Bryan MA, Ferguson A, Bayyari N, Taylor B, Snyder ME, Charron E, Adeoye-Olatunde OA, Ghitza UD, Winhusen TJ. Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO Alcohol, Smoking, and Substance Involvement Screening Test. Drug and Alcohol Dependence 2021;228:109067.
-
Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network task force report.
Joudrey PJ, Bart G, Brooner RK, Brown L, Dickson-Gomez J, Gordon A. Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network task force report. Substance Abuse 2021;42(3):245-254.
-
Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale.
Wang K, DiChiacchio T, Fang W, Lander L, Feinberg J, Xie C, Winstanley EL, Piamjariyakul U. Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale. Journal of Affective Disorders 2022;297:148-155.
-
Moderators of Treatment response to exercise in participants with stimulant use disorder: Exploratory results from the STimulant Reduction using Dosed Exercise (STRIDE) CTN-0037 study.
Rethorst CD, Henley SS, Carmody TJ, dela Cruz AM, Greer TL, Walker R, Stoutenberg M, Trivedi MH. Moderators of Treatment response to exercise in participants with stimulant use disorder: Exploratory results from the STimulant Reduction using Dosed Exercise (STRIDE) CTN-0037 study. Mental Health and Physical Activity 2021;21:100421.